Immunosuppressant therapeutic drug monitoring and trough level stabilisation after paediatric liver or kidney transplantation.


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
02 12 2019
Historique:
entrez: 5 12 2019
pubmed: 5 12 2019
medline: 12 5 2020
Statut: epublish

Résumé

Immunosuppressive therapy must be guided by therapeutic drug monitoring (TDM) in paediatric liver (LT) and kidney transplantation (KT) patients to prevent under- and overdosing, which have clinical consequences. The purpose of our study was to analyse TDM results in our institutions and evaluate factors associated with blood level stabilisation after LT and KT. Blood levels of immunosuppressants were measured by immunoassay analysis. We compared blood level stabilisation between LT and KT, and evaluated associated factors in a retrospective study in two Swiss university hospitals. Forty-six patients (27 LT [median age 1.0 y], 19 KT [15.1 y]) were included. During the first month after transplantation, 32.8% (LT) and 41.2% (KT) of tacrolimus, and 22.1% (KT) of ciclosporin trough levels (measured before the next dose) were within target. In KT, trough levels stabilised earlier for tacrolimus than for ciclosporin (p = 0.02). Intensive care and hospital discharge occurred earlier in KT patients (p <0.001). Living-donor LT was associated with an earlier intensive care discharge compared with deceased donor (5.5 vs 11 days, p = 0.02). Primary metabolic disease and graft/recipient weight-ratio ≥0.03 was associated with earlier tacrolimus level stabilisation (14 vs 18 days, p = 0.01 and 15 vs 22 days, p = 0.05, respectively). In KT, recipient age (≥15.1 years) and weight (≥39.4 kg) were associated with an earlier trough level stabilisation (both 13 days vs not reached, p <0.001), and age with earlier hospital discharge (10 vs 14 days, p = 0.02). Immunosuppressant trough levels were often outside the target range in the first month after LT and KT. Organ-specific factors were associated with trough stabilisation.

Sections du résumé

BACKGROUND
Immunosuppressive therapy must be guided by therapeutic drug monitoring (TDM) in paediatric liver (LT) and kidney transplantation (KT) patients to prevent under- and overdosing, which have clinical consequences.
AIM
The purpose of our study was to analyse TDM results in our institutions and evaluate factors associated with blood level stabilisation after LT and KT.
METHODS
Blood levels of immunosuppressants were measured by immunoassay analysis. We compared blood level stabilisation between LT and KT, and evaluated associated factors in a retrospective study in two Swiss university hospitals.
RESULTS
Forty-six patients (27 LT [median age 1.0 y], 19 KT [15.1 y]) were included. During the first month after transplantation, 32.8% (LT) and 41.2% (KT) of tacrolimus, and 22.1% (KT) of ciclosporin trough levels (measured before the next dose) were within target. In KT, trough levels stabilised earlier for tacrolimus than for ciclosporin (p = 0.02). Intensive care and hospital discharge occurred earlier in KT patients (p <0.001). Living-donor LT was associated with an earlier intensive care discharge compared with deceased donor (5.5 vs 11 days, p = 0.02). Primary metabolic disease and graft/recipient weight-ratio ≥0.03 was associated with earlier tacrolimus level stabilisation (14 vs 18 days, p = 0.01 and 15 vs 22 days, p = 0.05, respectively). In KT, recipient age (≥15.1 years) and weight (≥39.4 kg) were associated with an earlier trough level stabilisation (both 13 days vs not reached, p <0.001), and age with earlier hospital discharge (10 vs 14 days, p = 0.02).
CONCLUSION
Immunosuppressant trough levels were often outside the target range in the first month after LT and KT. Organ-specific factors were associated with trough stabilisation.

Identifiants

pubmed: 31800965
doi: 10.4414/smw.2019.20156
pii: Swiss Med Wkly. 2019;149:w20156
doi:
pii:

Substances chimiques

Immunosuppressive Agents 0
Cyclosporine 83HN0GTJ6D
Tacrolimus WM0HAQ4WNM

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

w20156

Auteurs

Klara M Posfay-Barbe (KM)

Paediatric Infectious Diseases Unit, Department of Paediatrics, Gynaecology and Obstetrics, University Hospitals of Geneva and Medical School of Geneva, Switzerland.

Henri Baudet (H)

Pharmacy, University Hospitals of Geneva, Switzerland / Faculty of Pharmacy, Paris Descartes University (Paris V), France.

Valérie A McLin (VA)

Paediatric Gastroenterology, Hepatology and Nutrition Unit, Department of Paediatrics, Gynaecology and Obstetrics, University Hospitals of Geneva and Medical School of Geneva, Switzerland.

Paloma Parvex (P)

Romand Paediatric Nephrology Unit, Department of Paediatrics, Gynecology and Obstetrics, University Hospitals of Geneva and Medical School of Geneva, Switzerland / Paediatric Nephrology Unit, Department of Paediatrics, CHUV, Lausanne, Switzerland.

Hassib Chehade (H)

Romand Paediatric Nephrology Unit, Department of Paediatrics, Gynecology and Obstetrics, University Hospitals of Geneva and Medical School of Geneva, Switzerland / Paediatric Nephrology Unit, Department of Paediatrics, CHUV, Lausanne, Switzerland.

Christophe Combescure (C)

Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland.

Pascal Bonnabry (P)

Pharmacy, University Hospitals of Geneva, Switzerland / School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.

Caroline Fonzo-Christe (C)

Pharmacy, University Hospitals of Geneva, Switzerland / Paediatric Intensive Care Unit, Department of Paediatrics, Gynaecology and Obstetrics, University Hospitals of Geneva and Medical School of Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH